141 related articles for article (PubMed ID: 21862876)
1. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
2. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
3. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA
Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293
[TBL] [Abstract][Full Text] [Related]
4. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
5. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
Gualdrini F; Corvetta D; Cantilena S; Chayka O; Tanno B; Raschellà G; Sala A
Oncotarget; 2010 Aug; 1(4):278-288. PubMed ID: 21304178
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
7. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
8. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.
Mandriota SJ; Valentijn LJ; Lesne L; Betts DR; Marino D; Boudal-Khoshbeen M; London WB; Rougemont AL; Attiyeh EF; Maris JM; Hogarty MD; Koster J; Molenaar JJ; Versteeg R; Ansari M; Gumy-Pause F
Oncotarget; 2015 Jul; 6(21):18558-76. PubMed ID: 26053094
[TBL] [Abstract][Full Text] [Related]
9. p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
Yogev O; Barker K; Sikka A; Almeida GS; Hallsworth A; Smith LM; Jamin Y; Ruddle R; Koers A; Webber HT; Raynaud FI; Popov S; Jones C; Petrie K; Robinson SP; Keun HC; Chesler L
Cancer Res; 2016 May; 76(10):3025-35. PubMed ID: 27197232
[TBL] [Abstract][Full Text] [Related]
10. Is MYCN Overexpression Associated With Poor Outcome in
Andrews A; Terry J
Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
[No Abstract] [Full Text] [Related]
11. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
Zhao M; Shu Y; Gu W; Tang H; Mao J
Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
[No Abstract] [Full Text] [Related]
12. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM
Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12664-9. PubMed ID: 15314226
[TBL] [Abstract][Full Text] [Related]
13. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
15. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
[TBL] [Abstract][Full Text] [Related]
16. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon E; Liang T; Jamin Y; Walz S; Kwok C; Hakkert A; Barker K; Urban Z; Thway K; Zeid R; Hallsworth A; Box G; Ebus ME; Licciardello MP; Sbirkov Y; Lazaro G; Calton E; Costa BM; Valenti M; De Haven Brandon A; Webber H; Tardif N; Almeida GS; Christova R; Boysen G; Richards MW; Barone G; Ford A; Bayliss R; Clarke PA; De Bono J; Gray NS; Blagg J; Robinson SP; Eccles SA; Zheleva D; Bradner JE; Molenaar J; Vivanco I; Eilers M; Workman P; Lin CY; Chesler L
J Clin Invest; 2020 Nov; 130(11):5875-5892. PubMed ID: 33016930
[TBL] [Abstract][Full Text] [Related]
17. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH
Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5.
Kanamori Y; Finotti A; Di Magno L; Canettieri G; Tahara T; Timeus F; Greco A; Tirassa P; Gasparello J; Fino P; Di Liegro CM; Proia P; Schiera G; Di Liegro I; Gambari R; Agostinelli E
Cells; 2021 Jul; 10(8):. PubMed ID: 34440719
[TBL] [Abstract][Full Text] [Related]
19. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
[TBL] [Abstract][Full Text] [Related]
20. MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma.
Liu T; Gu L; Wu Z; Albadari N; Li W; Zhou M
Front Oncol; 2022; 12():1058726. PubMed ID: 36505784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
